Share Issue/Capital Change • Dec 21, 2009
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
News Details
Corporate | 21 December 2009 16:48
Eckert & Ziegler: Shares from the capital increase authorised for trading (Prime Standard)
Eckert & Ziegler Strahlen- und Medizintechnik AG / Miscellaneous
21.12.2009
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
Berlin, 21.12.2009. The 1,350,000 shares issued in the course of the rights
issue from authorised capital resolved in November 2009 and entered in the
Commercial Register on December 10, 2009 were authorised for trading in the
regulated market (Prime Standard) of the Frankfurt Stock Exchange with
effect from December 21, 2009. The shares will be changed to the common
ISIN DE0005659700 effective from December 22, 2009. The notification of the
shares will take place also on December 22, 2009.
Eckert & Ziegler AG is one of the world's largest providers of isotope
component technology for radiation therapy and nuclear medicine and has
approx. 520 employees. For the current year, the company expects sales of
EUR 100 million and earnings per share of approx. EUR 1.80.
Eckert & Ziegler AG, Karolin Riehle, Investor Relations, Robert-Rössle-Str.
10, 13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, Fax -112, E-Mail: [email protected],
www.ezag.de
21.12.2009 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Deutschland
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: [email protected]
Internet: www.ezag.de
ISIN: DE0005659700, DE000A0L1L69
WKN: 565970, A0L1L6
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Düsseldorf, Hamburg
End of News DGAP News-Service
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.